A PILOT STUDY OF MYCOPHENOLATE MOFETIL IN CONGENITAL UROPATHIES

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 新的证据表明，在先天性尿路疾病的儿童中，炎症介质渗透到肾脏中，导致了这些患者肾功能的进行性下降。使用免疫抑制疗法来预防进行性非免疫性肾脏疾病的策略从未在涉及儿童或成人患者的临床实践中得到测试。这项研究旨在验证这样一种假设，即给先天性尿路疾病儿童使用霉酚酸酯(MMF)将是安全和有色的，并可能防止先天性尿路疾病患者肾功能的进行性下降。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Emerging evidence suggests that inflammatory mediators that infiltrate the kidney in children with congenital uropathies contribute to the progressive decline in kidney function that is observed in these patients. The strategy of using immunosuppressive therapy to protect against progressive, primary non-immunological forms of kidney disease has never been tested in clinical practice involving children or adult patients. This study is designed to test the hypothesis that administration of mycophenolate mofetil (MMF) to children with congenital uropathies will be safe and well tolorated and may prevent the progressive decline of kidney function in patients with congenital uropathies.